Aptarion Biotech AG

Quick facts

Phase 2 pipeline

• AON-D21 · Oncology
  AON-D21 is a small molecule that targets the PI3K/AKT/mTOR pathway.

Phase 1 pipeline

• Intravenous AON-D21

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Aptarion Biotech AG portfolio CI brief
• Aptarion Biotech AG pipeline updates RSS